MITIGATION STRATEGIES TO REDUCE CAR-T-CELL–RELATED TOXICITIES IN PATIENTS WITH B-CELL LYMPHOPROLIFERATIVE NEOPLASMS TREATED WITH AXI-CEL OR BREXU-CEL: A SINGLE-CENTER OBSERVATIONAL STUDY (SIE 2026) - Oct 6, 2026 - Abstract #SP082; "Data were collected prospec- tively and analyzed retrospectively.According to approved in- dications, 21 patients (median age 51 years, range 24–70) received lymphodepletion with fludarabine and cyclophos- phamide followed by autologous CD19-directed CAR T-cell infusion...Tocilizumab was re- quired in 19 patients (90%); 13 patients (61.9%) also re- quired dexamethasone for refractory symptoms. ICANS G1 occurred in 2 patients (9.5%) and only one required dexam- ethasone plus anakinra administration...At a median follow-up of 12.3 months, complete remission was documented in 13 patients (61.9%).Prophylactic dexamethasone and early IL1R antag- onist use may attenuate severe CRS and ICANS manifesta- tions following CAR T-cell infusion without compromising clinical benefit. Additional studies are needed to further vali- date these findings."
CAR T-Cell Therapy • Clinical • Observational data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • Primary Mediastinal Large B-Cell Lymphoma
|
|
A. M. E. Maraglino1; S. Sammassimo1; A. Clemente1; G. Lolli1; C. Cristinelli1; P. M. Nieryschlewska1; C. Steidl1; T. Radice1; S. Viviani1; R. Pastano1; A. Vanazzi1; E. Derenzini1,2
|